Loading
A phase 2 trial of capecitabine in triple-negative breast cancer, run by Fudan University, not yet recruiting.
Capecitabine in Low Risk Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT06787339 by Fudan University, with a registry enrolment figure of 198 participants, started 2025-01-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: Capecitabine. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically documented TNBC after early breast cancer surgery (absence of HER2, ER, and PR expression)". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/